Obesity therapeutics: Prospects and perspectives

被引：5

作者：

Duhl, DM ^{[1
]}

Boyce, RS ^{[1
]}

机构：

[1] Chiron Corp, Emeryville, CA 94608 USA

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38 | 2003年 / 38卷

关键词：

D O I：

10.1016/S0065-7743(03)38025-X

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：239 / 248

页数：10

共 64 条

[1] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].

Agerso, H ;

Jensen, LB ;

Elbrond, B ;

Rolan, P ;

Zdravkovic, M .

DIABETOLOGIA, 2002, 45 (02) :195-202

[2] Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents [J].

Ahn, JH ;

Cho, SY ;

Ha, JD ;

Chu, SY ;

Jung, SH ;

Jung, YS ;

Baek, JY ;

Choi, IK ;

Shin, EY ;

Kang, SK ;

Kim, SS ;

Cheon, HG ;

Yang, SD ;

Choi, JK .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (15) :1941-1946

[3] Annual deaths attributable to obesity in the United States [J].

Allison, DB ;

Fontaine, KR ;

Manson, JE ;

Stevens, J ;

VanItallie, TB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (16) :1530-1538

[4] Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B [J].

Andersen, HS ;

Olsen, OH ;

Iversen, LF ;

Sorensen, ALP ;

Mortensen, SB ;

Christensen, MS ;

Branner, S ;

Hansen, TK ;

Lau, JF ;

Jeppesen, L ;

Moran, EJ ;

Su, J ;

Bakir, F ;

Judge, L ;

Shahbaz, M ;

Collins, T ;

Vo, T ;

Newman, MJ ;

Ripka, WC ;

Moller, NPH .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (20) :4443-4459

[5] β3-adrenoceptor agonists:: potential, pitfalls and progress [J].

Arch, JRS .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 440 (2-3) :99-107

[6] Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].

Arnone, M ;

Maruani, J ;

Chaperon, F ;

Thiebot, MH ;

Poncelet, M ;

Soubrie, P ;

LeFur, G .

PSYCHOPHARMACOLOGY, 1997, 132 (01) :104-106

[7] Gut hormone PYY3-36 physiologically inhibits food intake [J].

Batterham, RL ;

Cowley, MA ;

Small, CJ ;

Herzog, H ;

Cohen, MA ;

Dakin, CL ;

Wren, AM ;

Brynes, AE ;

Low, MJ ;

Ghatei, MA ;

Cone, RD ;

Bloom, SR .

NATURE, 2002, 418 (6898) :650-654

[8] Anti-obesity drug development [J].

Bays, H ;

Dujovne, C .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (09) :1189-1204

[9] Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity [J].

Block, MH ;

Boyer, S ;

Brailsford, W ;

Brittain, DR ;

Carroll, D ;

Chapman, S ;

Clarke, DS ;

Donald, CS ;

Foote, KM ;

Godfrey, L ;

Ladner, A .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (16) :3509-3523

[10] Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist [J].

Borowsky, B ;

Durkin, MM ;

Ogozalek, K ;

Marzabadi, MR ;

DeLeon, J ;

Heurich, R ;

Lichtblau, H ;

Shaposhnik, Z ;

Daniewska, I ;

Blackburn, TP ;

Branchek, TA ;

Gerald, C ;

Vaysse, PJ ;

Forray, C .

NATURE MEDICINE, 2002, 8 (08) :825-830

← 1 2 3 4 5 6 7 →